Researchers Report on Impact of Bloodstream Infections in Complicating CDI
Clostridium difficile infection (CDI) and Klebsiella pneumoniae carbapenemase producing-Klebsiella pneumoniae (KPC-Kp) bloodstream infection (BSI) are emerging healthcare associated (HCA) diseases of public health concern, in terms of morbidity, mortality, and insufficient response to antibiotic therapy. Both agents can be acquired in the hospital but clinical disease can develop in a community setting, after discharge. Giuliano, et al. (2014) report a putative link between the aforementioned healthcare-associated infections that appeared as a dramatic community onset disease with a fulminant fatal outcome.
The researchers describe the case of a 63-year-old man affected by severe CDI. Even though the patient underwent 72 hours of standard CDI antibiotic treatment, the clinical course was complicated by toxic megacolon and KPC-Kp BSI. The patient died 24 hours after total colectomy.
The researchers say the impact of HCA-BSIs in complicating CDI is still unknown. Intestinal inflammatory injury and disruption of intestinal flora by standard antibiotic treatment could be responsible for promoting difficult-to-treat infections in CDI. By preserving intestinal flora, Fidaxomicin could have a crucial role in preventing BSIs complicating severe CDI. Their research was published in
Reference: Giuliano S, Guastalegname M, Jenco M, Morelli A, Falcone M and Venditti M. Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection. BMC Infectious Diseases 2014, 14:475 doi:10.1186/1471-2334-14-475
Newsletter
Related Articles
- Bug of the Month: I'm Older Than Empires
September 16th 2025
- Top 5 Infection Prevention Articles of Summer 2025
September 16th 2025
- From Outbreak to Zoopocalypse: 11 More Must-Watch Viral Thrillers
September 15th 2025
- Debunking the Mistruths and Misinformation About COVID-19
September 15th 2025
- Bug of the Month: I Like to Hitch a Ride
September 12th 2025